Oncoceutics Receives Foundation Grants to Establish an Expanded Access Program for ONC201 Philadelphia, PA (November 2, 2020) – Oncoceutics, a clinical-stage drug discovery and development company, announced today that it has received grants from Michael Mosier Defeat DIPG Foundation, Dragon Master Foundation and The ChadTough Foundation to fund an Expanded…
Candice Hamman and Carl Jansen VanVuuren tell the story of their son Owen who was diagnosed in June 2020 with DIPG, diffuse intrinsic pontine glioma. There are no treatment options besides the standard radiation and palliative care, and purchase of the experimental ONC201 from Germany. Candice and Carl share from…
Progress forward has come only from a collaborative effort by those who…could not turn away from this urgent, unmet need. How much larger the effort would be…if more people were aware, and more people and resources joined us in this fight. Dr. Michelle Monje, Associate Professor of Neurology, and by…
DIPG is a death sentence for children today, but it doesn’t have to be; this resolution is an important first step in securing the resources needed to develop better treatment options and find a cure. Congresswoman Jackie Speier (D-CA-14), leading sponsor of the DIPG Awareness Resolution Posted by the PNOC…
Anjalie Bartee was a normal, healthy 17-year-old, a junior in high school in Omaha, NE when she began experiencing headaches and vision changes. Her doctor thought it might be due to recent changes in her medication, but the condition persisted and worsened; the ophthalmologist detected pressure on the brain and…
Chance Mazzell and his wife Heather share with us the story of their daughter Olivia and the places that DIPG, diffuse intrinsic pontine glioma, has led them. Olivia was diagnosed with DIPG on August 28th of 2018; her journey was particularly difficult out of the gate. The Mazzells, from Lexington,…
Joshua Allen, Senior Vice President of Research and Development at Oncoceutics joins us to explain a novel group of compounds called imipridones that he helped to create which target specific mutations in an wide array of cancer types. ONC201, the first that he personally discovered, is now being used in…
